Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label NVG-2089 study in chronic inflammatory demyelinating polyneuropathy
ACTRN12625000534482Phase 2Not yet recruiting
- Sponsor
- Nuvig Therapeutics
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Nuvig Therapeutics. Primary endpoints: Safety of NVG-2089 and Tolerability of NVG-2089. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
NVG-2089
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ACTRN12625000534482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000534482.